Eldorado Hotel & Spa Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2020
Here are the related meetings in 2021:
MEETING CHANGE TO VIRTUAL: Tuberculosis: Science Aimed at Ending the Epidemic (S9)
Tuberculosis: Science Aimed at Ending the Epidemic (EK10)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Tuberculosis: Immunity and Immune Evasion (A2)
Organizer(s) Joel Ernst, Jennifer Philips and Daniel L. Barber
January 16—20, 2020
Eldorado Hotel & Spa • Santa Fe, NM USA
Discounted Abstract Deadline: Sep 24, 2019
Abstract Deadline: Oct 16, 2019
Scholarship Deadline: Sep 24, 2019
Discounted Registration Deadline: Nov 19, 2019
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Summary of Meeting:
Tuberculosis remains the most common fatal infectious disease worldwide due to the absence of a sufficiently effective vaccine. Two critical barriers to the development of an effective TB vaccine are the incomplete understanding of the mechanisms of protective immunity to TB, and of the mechanisms of immune evasion by M. tuberculosis. The interactions among speakers and attendees at this conference will promote collaborations between scientists with complementary expertise who work in geographically distinct institutions, including those in high TB burden regions. This conference will present new findings on mechanisms of protective immunity to M. tuberculosis, and promote dialogue between immunologists and scientists in different areas of expertise to fill gaps in knowledge. Participants will also discuss advances in TB vaccine development and vaccine immunology. Finally, this conference will cover advances in other fields of immunology and other infectious diseases characterized by pathogen persistence, which will help to inform development of effective TB vaccines.
View Scholarships/Awards
Tuberculosis remains the most common fatal infectious disease worldwide due to the absence of a sufficiently effective vaccine. Two critical barriers to the development of an effective TB vaccine are the incomplete understanding of the mechanisms of protective immunity to TB, and of the mechanisms of immune evasion by M. tuberculosis. The interactions among speakers and attendees at this conference will promote collaborations between scientists with complementary expertise who work in geographically distinct institutions, including those in high TB burden regions. This conference will present new findings on mechanisms of protective immunity to M. tuberculosis, and promote dialogue between immunologists and scientists in different areas of expertise to fill gaps in knowledge. Participants will also discuss advances in TB vaccine development and vaccine immunology. Finally, this conference will cover advances in other fields of immunology and other infectious diseases characterized by pathogen persistence, which will help to inform development of effective TB vaccines.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Thursday, January 16 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Monday, January 20 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Tuesday, January 21 in order to fully experience the meeting.
THURSDAY, JANUARY 16
FRIDAY, JANUARY 17
SATURDAY, JANUARY 18
SUNDAY, JANUARY 19
MONDAY, JANUARY 20
TUESDAY, JANUARY 21
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Thursday, January 16 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Monday, January 20 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Tuesday, January 21 in order to fully experience the meeting.
THURSDAY, JANUARY 16
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address
*
Joel D. Ernst,
University of California, San Francisco, USA
Eric Goosby,
University of California, San Francisco / United Nations, USA
Global Solutions to Elimination of Tuberculosis: The Roles of Immunology and Vaccines
Global Solutions to Elimination of Tuberculosis: The Roles of Immunology and Vaccines
09:00—11:00
TB Vaccines and Vaccine Immunology
*
Joel D. Ernst,
University of California, San Francisco, USA
Patricia A. Darrah,
NIAID, National Institutes of Health, USA
Evaluating Mechanisms of Protection after Intravenous BCG Immunization in Nonhuman Primates
Evaluating Mechanisms of Protection after Intravenous BCG Immunization in Nonhuman Primates
Coffee Break
Thomas J. Scriba,
University of Cape Town, South Africa
Immune Responses to Diverse TB Vaccines in Humans
Immune Responses to Diverse TB Vaccines in Humans
Ann M. Ginsberg,
Bill & Melinda Gates Foundation, USA
TB Vaccine Human Efficacy Trials: What Have We Learned? Where Are We Headed?
TB Vaccine Human Efficacy Trials: What Have We Learned? Where Are We Headed?
14:30—16:30
Workshop 1: Moving Beyond Th1 Immunity in TB
*
Andrew Olive,
Michigan State University, USA
Shi-Hsia Hwa,
Africa Health Research Institute, South Africa
Human Serum and Monoclonal Antibodies Can Inhibit Intracellular Mycobacterium Tuberculosis Growth and Promote Phagocyte Survival
Human Serum and Monoclonal Antibodies Can Inhibit Intracellular Mycobacterium Tuberculosis Growth and Promote Phagocyte Survival
Hao Li,
China Agricultural University, China
Isolation and Functional Characterization of Fully Human Protective Monoclonal Antibodies Directed against the Surface of Mycobacterium tuberculosis
Isolation and Functional Characterization of Fully Human Protective Monoclonal Antibodies Directed against the Surface of Mycobacterium tuberculosis
Rachel L. Tanner,
University of Oxford, UK
Characterising the BCG-Induced Humoral Immune Response to Inform the Design of Improved TB Vaccines
Characterising the BCG-Induced Humoral Immune Response to Inform the Design of Improved TB Vaccines
Paula Ruibal,
Leiden University Medical Center, Netherlands
Identification of Novel HLA-E Binding Mtb-Derived Peptides as Potential Vaccine Candidates
Identification of Novel HLA-E Binding Mtb-Derived Peptides as Potential Vaccine Candidates
Shunsuke Sakai,
NIAID, National Institutes of Health, USA
Immunoregulatory and Host-Protective Functions of MAIT Cells during Mycobacterium tuberculosis Infection
Immunoregulatory and Host-Protective Functions of MAIT Cells during Mycobacterium tuberculosis Infection
David M. Lewinsohn,
Oregon Health & Science University, USA
Presentation of Mtb-Derived Antigens to MR1T Cells: A Unique Role for Endosomal Trafficking, and an Inhibitory Role for the MR1B Splice Variant
Presentation of Mtb-Derived Antigens to MR1T Cells: A Unique Role for Endosomal Trafficking, and an Inhibitory Role for the MR1B Splice Variant
Michael C. Kiritsy,
University of Massachusetts Medical School, USA
Dissecting Host Innate Immunity to Tuberculosis Using Engineered and Natural Genetic Variation
Dissecting Host Innate Immunity to Tuberculosis Using Engineered and Natural Genetic Variation
Daniel F. Hoft,
St. Louis University, USA
A Human BCG Challenge Model to Assess TB Vaccines and Identify Immune Biomarkers
A Human BCG Challenge Model to Assess TB Vaccines and Identify Immune Biomarkers
17:00—19:00
Impact of Host and Pathogen Diversity
*
Thuong T. T. Nguyen,
Oxford University Clinical Research Unit, Vietnam
Chetan Seshadri,
University of Washington, USA
IFN-γ-Independent Immune Markers of Mycobacterium tuberculosis Exposure
IFN-γ-Independent Immune Markers of Mycobacterium tuberculosis Exposure
Sara Suliman,
Brigham and Women's Hospital, USA
Human Genetic and Transcriptional Correlates of TB Progression
Human Genetic and Transcriptional Correlates of TB Progression
Shabaana Khader,
Washington University School of Medicine, USA
Role of Innate Lymphoid Cells in Tuberculosis
Role of Innate Lymphoid Cells in Tuberculosis
Sarah M. Fortune,
Harvard TH Chan School of Public Health, USA
Single Cell RNAseq Reveals Novel Correlates of TB Granuloma Fate
Single Cell RNAseq Reveals Novel Correlates of TB Granuloma Fate
08:00—11:00
Mechanisms of T Cell Protection
*
Cheryl L. Day,
Emory University, USA
Marc K. Jenkins,
University of Minnesota Medical School, USA
CD4+ T Cell-Based Control of a Phagosomal Pathogen
CD4+ T Cell-Based Control of a Phagosomal Pathogen
Cecilia S. Lindestam Arlehamn,
La Jolla Institute for Allergy and Immunology, USA
T Cell Transcriptomics Reveal Immune Signatures of Tuberculosis
T Cell Transcriptomics Reveal Immune Signatures of Tuberculosis
Coffee Break
Daniel L. Barber,
NIAID, National Institutes of Health, USA
Protective CD4 T Cell Responses to M. tuberculosis Infection
Protective CD4 T Cell Responses to M. tuberculosis Infection
Paul Ogongo,
University of California, San Francisco, USA
Compartmentalization of M. tuberculosis-Specific Human T-Cells in the Lung
Compartmentalization of M. tuberculosis-Specific Human T-Cells in the Lung
Munyaradzi Nyasha Musvosvi,
University of Cape Town, South Africa
Short Talk: Mycobacteria-Specific T Cell Receptor Clonotypes Associated with Mycobacterium tuberculosis Infection Outcome
Short Talk: Mycobacteria-Specific T Cell Receptor Clonotypes Associated with Mycobacterium tuberculosis Infection Outcome
Christine Nelson,
NIAID, National Institutes of Health, USA
Short Talk: CD226 and CD28 Have Opposing Roles in the Generation of Lung-Homing CD4 T Cells during M. tuberculosis Infection
Short Talk: CD226 and CD28 Have Opposing Roles in the Generation of Lung-Homing CD4 T Cells during M. tuberculosis Infection
15:00—16:30
Workshop 2: Impact of Coinfections and Comorbidities on TB Immunity
*
Blanca I. Restrepo,
University of Texas HSC Houston, Brownsville Campus, USA
Taryn A. McLaughlin,
Emory University, USA
CD4 T Cells in Mycobacterium tuberculosis and Schistosoma Mansoni Co-Infected Individuals Maintain Functional TH1 Responses
CD4 T Cells in Mycobacterium tuberculosis and Schistosoma Mansoni Co-Infected Individuals Maintain Functional TH1 Responses
Deepak Tripathi,
University of Texas Health Science Center at Tyler, USA
IL-22 Produced by Type 3 Innate Lymphoid Cells (ILC3s) Reduces the Mortality of Type 2 Diabetes Mellitus (T2DM) Mice Infected with Mycobacterium tuberculosis
IL-22 Produced by Type 3 Innate Lymphoid Cells (ILC3s) Reduces the Mortality of Type 2 Diabetes Mellitus (T2DM) Mice Infected with Mycobacterium tuberculosis
Mohau Steven Makatsa,
University of Cape Town, South Africa
Characterization of Mtb-Specific Th22 Cells in HIV and TB Co-Infection
Characterization of Mtb-Specific Th22 Cells in HIV and TB Co-Infection
Susana Benet,
Irsicaixa, Spain
Impact of Siglec-1 Variant on Disseminated Tuberculosis during HIV-1 Co-Infection
Impact of Siglec-1 Variant on Disseminated Tuberculosis during HIV-1 Co-Infection
Charles A. Scanga,
University of Pittsburgh School of Medicine, USA
Vaccination with Intravenous BCG Confers Remarkable Protection from Tuberculosis in SIV+ Macaques
Vaccination with Intravenous BCG Confers Remarkable Protection from Tuberculosis in SIV+ Macaques
Robert Blomgran,
Linköping University, Sweden
Beneficial Effects of Helminth Antigen Exposure for the Control of Mycobacterium tuberculosis Infection in Monocytes and Macrophages, Contrasting the Effect of Chronic Helminth Infection
Beneficial Effects of Helminth Antigen Exposure for the Control of Mycobacterium tuberculosis Infection in Monocytes and Macrophages, Contrasting the Effect of Chronic Helminth Infection
17:00—19:15
Immunometabolism and Host-Directed Therapies
*
Tom H. M. Ottenhoff,
Leiden University Medical Center, Netherlands
Amit Singhal,
Singapore Immunology Network, Singapore
Reprograming Host Immunometabolic Circuits for Designing TB HDT
Reprograming Host Immunometabolic Circuits for Designing TB HDT
Sarah A. Stanley,
University of California, Berkeley, USA
Metabolic Regulation of Macrophage Activation during Mtb Infection
Metabolic Regulation of Macrophage Activation during Mtb Infection
Jennifer Philips,
Washington University School of Medicine, USA
Targeting Host Metabolism to Treat TB
Targeting Host Metabolism to Treat TB
Jeffey M. Collins,
Emory University School of Medicine, USA
Short Talk: Tryptophan Catabolism Reflects Disease Activity and Treatment Response in Latent Infection and Active Disease Caused by Mycobacterium tuberculosis
Short Talk: Tryptophan Catabolism Reflects Disease Activity and Treatment Response in Latent Infection and Active Disease Caused by Mycobacterium tuberculosis
Katharina Ronacher,
University of Queensland, Australia
Short Talk: Identification of a Putative Target for Host-Directed Therapy: A Cholesterol Receptor Regulates Interferons and Bacterial Growth during M. tuberculosis Infection
Short Talk: Identification of a Putative Target for Host-Directed Therapy: A Cholesterol Receptor Regulates Interferons and Bacterial Growth during M. tuberculosis Infection
Hua Yang,
Shanghai Pulmonary Hospital, Tongji University School of Medicine, China
Short Talk: Interception of Host Fatty Acid Metabolism by Mycobacteria Under Hypoxia to Suppress Anti-TB Immunity
Short Talk: Interception of Host Fatty Acid Metabolism by Mycobacteria Under Hypoxia to Suppress Anti-TB Immunity
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Lessons from Beyond TB
*
Sarah A. Stanley,
University of California, Berkeley, USA
Steven M. Holland,
NIAID, National Institutes of Health, USA
Are Infections in the Lung and Outside it the Same? Host Factors in Mycobacterial Tissue Specificity
Are Infections in the Lung and Outside it the Same? Host Factors in Mycobacterial Tissue Specificity
Nevil J. Singh,
University of Maryland, USA
The Signaling Logic Regulating T Cell Responses to Persistent Antigens
The Signaling Logic Regulating T Cell Responses to Persistent Antigens
Coffee Break
David L. Sacks,
NIAID, National Institutes of Health, USA
Dermis Resident Macrophages are Maintained as a Replicative Niche for Leishmania in a Th1 Immune Environment
Dermis Resident Macrophages are Maintained as a Replicative Niche for Leishmania in a Th1 Immune Environment
Haina Shin,
Washington University, USA
Distinct Host Restriction of HSV-1 and HSV-2 Genital Herpes
Distinct Host Restriction of HSV-1 and HSV-2 Genital Herpes
Lara Mittereder,
Food and Drug Administration, USA
Short Talk: Primed Lymphocytes That Control Intramacrophage Bacterial Replication Shift Metabolism toward Glycolysis
Short Talk: Primed Lymphocytes That Control Intramacrophage Bacterial Replication Shift Metabolism toward Glycolysis
Erika J. Hughes,
Duke University, USA
Short Talk: Single-Cell RNA-Seq of Zebrafish Granulomas Reveals Altered Cell Composition and Inflammatory Expression Profiles Associated with Dysregulated Eicosanoid Signaling
Short Talk: Single-Cell RNA-Seq of Zebrafish Granulomas Reveals Altered Cell Composition and Inflammatory Expression Profiles Associated with Dysregulated Eicosanoid Signaling
Ya-Ting Wang,
Washington University School of Medicine, USA
Short Talk: Redefining the Role of Autophagy in Infectious Disease
Short Talk: Redefining the Role of Autophagy in Infectious Disease
17:00—19:00
Mechanisms of T Cell Evasion
*
Daniel L. Barber,
NIAID, National Institutes of Health, USA
Joel D. Ernst,
University of California, San Francisco, USA
Partners of T Cells: Functional Diversity of Mononuclear Phagocytes in Chronic M. tuberculosis Infection
Partners of T Cells: Functional Diversity of Mononuclear Phagocytes in Chronic M. tuberculosis Infection
Samuel M. Behar,
University of Massachusetts Medical School, USA
Differential Presentation of M. tuberculosis Antigens to T Cells During Priming and Chronic Infection
Differential Presentation of M. tuberculosis Antigens to T Cells During Priming and Chronic Infection
Kevin B. Urdahl,
Seattle Children's Research Institute, USA
Barriers to Immunity in the TB Granuloma
Barriers to Immunity in the TB Granuloma
Björn Corleis,
Friedrich-Loeffler Institute, Germany
Short Talk: Tobacco Smoke Leads to Recruitment of Inflammatory Monocytes into the Alveolar Space and Accelerates Growth of Mycobacterium Tuberculosis
Short Talk: Tobacco Smoke Leads to Recruitment of Inflammatory Monocytes into the Alveolar Space and Accelerates Growth of Mycobacterium Tuberculosis
Ana Beatriz Enriquez,
Emory University, USA
Short Talk: Mycobacterium tuberculosis Modulation of Notch Ligand Expression Impedes Dendritic Cell-T Cell Crosstalk and Limits Th17 Polarization
Short Talk: Mycobacterium tuberculosis Modulation of Notch Ligand Expression Impedes Dendritic Cell-T Cell Crosstalk and Limits Th17 Polarization
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Pathogen Determinants of Immune Evasion
*
Jennifer Philips,
Washington University School of Medicine, USA
Steven A. Porcelli,
Albert Einstein College of Medicine, USA
Mycobacterial PE_PGRS Proteins in Evasion of Innate and Adaptive Immunity
Mycobacterial PE_PGRS Proteins in Evasion of Innate and Adaptive Immunity
Olivier Neyrolles,
IPBS, CNRS-University of Toulouse, France
C-Type Lectin Receptors in Immunity to Tuberculosis
C-Type Lectin Receptors in Immunity to Tuberculosis
Coffee Break
Maximiliano Gutierrez,
Francis Crick Institute, UK
Mycobacterium tuberculosis Evasion of Xenophagy in the Cytosol of Host Cells
Mycobacterium tuberculosis Evasion of Xenophagy in the Cytosol of Host Cells
Oren S. Rosenberg,
University of California, San Francisco, USA
TB from the Inside Out: Structural Biology of ESX Secretion
TB from the Inside Out: Structural Biology of ESX Secretion
Volker Briken,
University of Maryland, USA
Short Talk: A Molecular Mechanism of Mycobacterium tuberculosis Mediated Inflammasome Inhibition
Short Talk: A Molecular Mechanism of Mycobacterium tuberculosis Mediated Inflammasome Inhibition
Jeffrey Buter,
University of Groningen, Netherlands
Short Talk: M. Tuberculosis Antacids Block Autophagy and Promote Lipid Accumulation in Foamy Macrophages
Short Talk: M. Tuberculosis Antacids Block Autophagy and Promote Lipid Accumulation in Foamy Macrophages
15:00—16:30
Workshop 3: New Technologies and Models in TB Immunity
*
Oren S. Rosenberg,
University of California, San Francisco, USA
Amanda J. Martinot,
Tufts Cummings School of Veterinary Medicine, USA
Cyclic Immunofluorescence: in situ Multiplex Immunophenotyping of Cells in TB Granulomas
Cyclic Immunofluorescence: in situ Multiplex Immunophenotyping of Cells in TB Granulomas
Erin F. McCaffrey,
Stanford University, USA
Characterization of the Composition and Structure of Human Tuberculosis Granulomas with Multiplexed Ion Beam Imaging
Characterization of the Composition and Structure of Human Tuberculosis Granulomas with Multiplexed Ion Beam Imaging
Sherry L. Kurtz,
Food & Drug Administration, USA
Genetically Diverse DO Mice Are a Novel Model for Studying Tuberculosis Vaccines and for Defining Genetic Traits Associated with Vaccine-Induced Protection
Genetically Diverse DO Mice Are a Novel Model for Studying Tuberculosis Vaccines and for Defining Genetic Traits Associated with Vaccine-Induced Protection
Mohamed Ahmed,
Africa Health Research Institute, South Africa
Sensing of Interferon-gamma by Mycobacterium tuberculosis
Sensing of Interferon-gamma by Mycobacterium tuberculosis
Paulo Bettencourt,
University of Oxford, UK
Immunopeptidomics-Based Identification of Antigens Presented by MHC-I and MHC-II for Vaccines against Tuberculosis
Immunopeptidomics-Based Identification of Antigens Presented by MHC-I and MHC-II for Vaccines against Tuberculosis
Mark Hatherill,
University of Cape Town, South Africa
Biomarker-Targeted Tuberculosis Preventive Therapy: A Randomized, Partially-Blinded Clinical Trial
Biomarker-Targeted Tuberculosis Preventive Therapy: A Randomized, Partially-Blinded Clinical Trial
17:00—18:45
Trained Immunity and Control of TB
Mihai G. Netea,
Radboud University, Netherlands
Trained Immunity: A Memory for Innate Host Defense
Trained Immunity: A Memory for Innate Host Defense
Maziar Divangahi,
McGill University, Canada
M. tuberculosis Reprograms HSCs to Limit Myelopoiesis and Impair Trained Immunity
M. tuberculosis Reprograms HSCs to Limit Myelopoiesis and Impair Trained Immunity
Simone A. Joosten,
Leiden University Medical Center, Netherlands
Trained Immunity in TB Exposure
Trained Immunity in TB Exposure
*
Alissa C. Rothchild,
Seattle Children's Research Institute, USA
Short Talk: Alveolar Macrophages Up-Regulate a Non-Classical Innate Response to Mycobacterium tuberculosis Infection in vivo
Short Talk: Alveolar Macrophages Up-Regulate a Non-Classical Innate Response to Mycobacterium tuberculosis Infection in vivo
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
